Artificial intelligence systems are beginning to function as “co-scientists” in cancer research, generating drug candidates, prioritizing immunotherapy targets, and guiding experimental design.
Cancer Res (2022) 82 (12_Supplement): 5443.
2020 Meetings Abstracts: AACR Special Conference on Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies January 9–12, 2020; San Diego, CA ...
Cancer Discov (2026) 16 (2): OF1.
Abstract. Hematopoietic stem cells (HSC) and T cells are intimately related, lineage-dependent cell populations that are extensively used as therapeutic products for the treatment of hematologic ...
Mitochondrial glutathione import via SLC25A39 supports breast cancer metastasis by linking glutathione availability to ATF4-driven integrated stress response signaling during early metastatic ...
Abstract. Binding of steroid hormones to their cognate receptors regulates the growth of most prostate and breast cancers. We hypothesized that CYP11A inhibition might halt the synthesis of all ...
Infrequently mutated genes comprise most of the mutational burden in breast tumors but are poorly understood. In vivo CRISPR screening identified functional tumor suppressors that converged on ...
Neuronal pentraxin 1 (NPTX1) is identified as a therapeutically druggable driver of pancreatic cancer metastatic colonization through its action on the receptor AMIGO2, which promotes HIF-1α nuclear ...
1Genentech, Inc., South San Francisco, CA. Search for other works by this author on: ...
Cancer Res (2023) 83 (8_Supplement): LB215.
Washington University In St. Louis, St. Louis, MO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results